Download MendeleyDiscovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.
Tyhonas, J.S., Arnold, L.D., Cox, J.M., Franovic, A., Gardiner, E., Grandinetti, K., Kania, R., Kanouni, T., Lardy, M., Li, C., Martin, E.S., Miller, N., Mohan, A., Murphy, E.A., Perez, M., Soroceanu, L., Timple, N., Uryu, S., Womble, S., Kaldor, S.W.(2024) J Med Chem 67: 1734-1746
- PubMed: 38267212
- DOI: https://doi.org/10.1021/acs.jmedchem.3c01819
- Primary Citation of Related Structures:
8UDT, 8UDU, 8UDV - PubMed Abstract:
Fibroblast growth factor receptor (FGFR) alterations are present as oncogenic drivers and bypass mechanisms in many forms of cancer. These alterations can include fusions, amplifications, rearrangements, and mutations. Acquired drug resistance to current FGFR inhibitors often results in disease progression and unfavorable outcomes for patients. Genomic profiling of tumors refractory to current FGFR inhibitors in the clinic has revealed several acquired driver alterations that could be the target of next generation therapeutics. Herein, we describe how structure-based drug design (SBDD) was used to enable the discovery of the potent and kinome selective pan-FGFR inhibitor KIN-3248 , which is active against many acquired resistance mutations. KIN-3248 is currently in phase I clinical development for the treatment of advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.
Organizational Affiliation:
Kinnate Biopharma, San Diego, California 92130, United States.
